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Strengths and limitations of this study
 ► This is a first study in Nepal to explore hormone use 
in transgender women.
 ► We invited participants from four of the seven prov-
inces; therefore, our data include diverse views, cov-
ering all major ethnic groups.
 ► Despite Nepal being a conservative country, our 
focus group discussions and interviews generated 
rich data due to the active involvement of the partic-
ipants in this research.
 ► Participants were invited through a local organi-
sation that works for the transgender community; 
therefore, they may be more exposed to health and 
social issues than other transgender women.
 ► All researchers were male, which may have influ-
enced the data collection.
AbStrACt
Objectives There is a dearth of information on 
transgender individuals in Nepal, particularly studies 
exploring their use of hormone therapies. The objectives 
of this study therefore were to explore (1) how hormones 
are used, (2) types of hormones used and (3) side effects 
experienced by transgender women after hormone use. 
This is the first study of its kind in Nepal addressing this 
important public health issue.
Setting The study was conducted in four districts of 
Nepal: Kathmandu, Sunsai, Banke and Kaski.
Design and participants This qualitative study comprises 
eight focus group discussions (FGDs) and nine interviews. 
FGDs and three face-to-face interviews were held with 
transgender women aged 18 years and older and six 
interviews with stakeholders working with and advocating 
on behalf of this population. The study was conducted 
between September 2016 and March 2017.
results Our participants were young. The majority of 
FGD participants had completed school-level education 
and 40% had been using hormones for 1 to 3 years. 
Five overlapping themes were identified: (1) reasons and 
motivations for hormone use; (2) accessibility and use of 
hormones; (3) side effects; (4) utilisation of healthcare 
services and (5) discontinuation of hormone use.
Conclusion Hormone use was common in our sample. 
Most received information on hormone therapy online 
and through their peer networks. A few study participants 
sought doctors’ prescriptions for hormone therapy, but 
hormones were more likely to be bought from local 
private pharmacies or abroad through friends. This kind 
of self-medication is associated with a range of risks to 
the physical and mental health of transgender individuals. 
Incorporating information, education and communication 
about hormone therapy into existing health promotion 
interventions targeted to this population may help 
transgender people to make better informed choices.
IntrODuCtIOn
Transgender individuals are defined as 
‘people whose gender identify and gender 
expression differ from their biological sex 
at birth’. They may be classified as ‘male to 
female (MTF) transgender’, that is, being 
assigned the male sex at birth but identifying 
as female or ‘female to male (FTM) trans-
gender’, people being assigned the female sex 
at birth but identifying as male.1 2 However, 
there is a lack of consensus on a universally 
accepted definition for individual who 
identify as transgender due to their diverse 
sexual orientation identities, attraction and 
behaviours.3 The ambiguity around defini-
tions, combined with discrimination of trans-
gender populations, reflects social taboos, 
which makes it difficult to estimate both 
the national and global prevalence of trans-
gender identity.4 5 In the USA, studies suggest 
a prevalence of 0.4% to 0.6% for people who 
identify as transgender.6 Extrapolating the US 
prevalence proportion to the global popula-
tion, Winter and colleagues5 have recently 
calculated that there is some 25 million trans 
people worldwide. The recent proposal to 
shift descriptive elements of transgender 
identity from ‘mental health disorders’ Inter-
national Classification of Diseases (ICD-10) 
to ‘sexual health categories’ (ICD-11) may 
reduce stigma and serve as a useful instru-
ment to estimate the size of this population.7 8
Health and well-being of transgender individuals 
in nepal
Over the past decades, Nepal has witnessed 
significant legal reforms that affirm rights of 
its sexual and gender minority (SGM) popu-
lations including lesbian, gay, bisexual and 
transgender. The new Constitution of Nepal 
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impressively recognised the rights of SGM as funda-
mental.9 Nepal acknowledges its transgender commu-
nity by allowing a third category of ‘others’ (meaning 
gender other than male or female) on passports, citizen-
ship certificates, electoral rolls and immigration forms. 
In addition, the Nepal Health Policy (2014) and other 
strategic documents such as the Nepal Health Sector 
Strategy 2016–2020 have enshrined several rights for 
SGM.10 11 Yet, trans individuals in Nepal are often stig-
matised or discriminated against while accessing health 
and social care services. Healthcare providers are poorly 
trained on issues of transgender.12 Furthermore, since 
society is generally conservative and condemns sexual 
orientation other than heterosexuality, it can be diffi-
cult for trans people to seek public services13 as they fear 
discrimination.12
The general health of transgender people is generally 
an under-research area.1 14 Until recently, most research 
on transgender populations in Nepal or other South 
Asian countries has focused on HIV, sexual behaviour 
and mental health, largely due to the disproportionate 
prevalence of HIV in transgender individuals.6 It has 
been estimated that transgender individuals in low-in-
come and middle-income countries (LMICs) are 50 times 
more likely to be infected with HIV than other adults of 
reproductive age.15 This risk is also mirrored in the recent 
Integrated Biological and Behavioural Survey (IBBS) of 
Nepal which reported a higher HIV prevalence (11.5%) 
in transgender individuals than other key populations 
such as injecting drug users, men who have sex with 
men (MSM) and sex workers.16 Similarly, a study with 
232 Nepali trans people found that one-third had sexual 
intercourse with more than one sex partner per day.17 
Utilisation of HIV Testing and Counselling services by 
Nepal’s transgender population is also poor.18
Few studies report on sexual-orientation-based discrim-
ination in public places experienced by Nepali trans indi-
viduals. For example, of the 139 transgender participants 
included in the Nepali IBBS study, 63% experienced 
discrimination on the street or in parks. About one-third 
(30%) experienced similar problems while seeking 
medical care.16 Studies also documented that compared 
with MSM, a higher proportion of transgender individ-
uals in Nepal experiences suicidal ideation (39.8% vs 
21.3%) or attempts suicide (15.3% vs 6.4%),19 while in the 
2018 IBBS study, suicidal ideation among this group was 
as high as 41.7%.16 Global evidence suggests that trans-
gender individuals have a higher prevalence of mental 
health problems.1 20–23 One US study, for example, with 
230 transgender women, showed a high depression rate 
(63% had Center for Epidemiological Studies Depression 
(CESD) 20 or higher).21 Anxiety levels are also commonly 
higher than in the general population, a systematic review 
reported prevalence rates in transgender populations 
ranging from 17% to 68%.24
To the best of our knowledge, none of the studies have 
examined the mental health status of Nepali transgender 
individuals using validated tools. In addition, tobacco and 
alcohol consumption are also widespread in the Nepali 
transgender population.17
Hormone therapy by nepali transgender women
Transgender women, also known as trans women, may 
use different therapies to medically affirm their gender 
identity through feminisation of their appearance. 
Hormone therapy, injecting silicone, gender-affirmation 
surgery, breast augmentation, mechanical therapy for 
body or facial hair, and voice therapy are thought to be 
common.25–27 However, due to the high costs especially for 
gender-affirming surgery and the experience of health-
care-related stigma, many transgender people in LMICs 
cannot or would not seek gender-affirming care.28–30
Hormone therapy induces the characteristics of the 
affirmed gender and reduces the characteristics of an 
individual’s birth sex. Two classes of medications are most 
commonly used by trans women: (1) oestrogen therapies 
and (2) androgen-lowering hormone therapies. This is 
often in combination with progesterone therapies as a 
secondary agent to lower testosterone concentrations.31 
For trans women, feminising treatments usually involve 
the use of oestrogen and an androgen blocker.32
The number of people using cross-sex hormone therapy 
worldwide has risen over the years.33 In Asia, studies in 
Thailand report 73%–94% hormone use among trans 
women.2 34 35 The wider availability of hormones without 
prescription has most likely also resulted in an increased 
use in this population. In Nepal, ‘hormones’ are classified 
as a ‘b’ category medicine only available on prescription. 
This is in line with the framework developed by the Endo-
crine Society and the World Professional Association for 
Transgender Health (WPATH).36 In reality, only about 
one in five transgender individuals in Nepal were advised 
by a doctor to use hormones, while the overwhelming 
majority relied on non-medical advice.16 In practice, 
hormones are easily available from private pharmacists in 
Nepal without prescription.37
However, there is a dearth of research on the expe-
rience of hormone use or other therapies among 
transgender individuals in Nepal. Studies from other 
geographical settings on hormone use by transgender 
individuals have yielded mixed outcomes. For example, 
a study in France found a positive effect of hormone 
therapy on their quality of life (QoL).38 However, such 
QoL studies do not exist in Nepal. Emerging evidence 
shows that hormone use is associated with numerous 
health risks such as venous thromboembolism, elevated 
liver enzymes, gallstones, decrease in haemoglobin, low 
sexual desire, reduction in facial/body hair, increased 
rate of myocardial infarction or depression.31 39 40 Where 
hormones are difficult to access with a prescription, 
transgender population seek and use hormones in less 
safe ways. For example, in Chicago, 71% of trans women 
reported obtaining hormones from a non-medical 
source in the past year41; similarly, 58% of trans women 
in Virginia reported ever having used non-prescribed 
hormones.42 Although the literature on needle sharing 
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Table 1 Number of FGD and participants by study areas
Participants by district N (%)
Kathmandu (5 FGD) 39 (62.9)
Kaski (1 FGD) 7 (11.3)
Banke (1 FGD) 8 (12.9)
Sunsari (1 FGD) 8 (12.9)
Total participants 62 (100)
FGD, focus group discussion.
in trans populations is sparse, sharing needles to inject 
hormones could increase the risk of acquiring infectious 
diseases.43 The degree of interactions between hormones 
and antiretroviral therapy in the transgender population 
is another area of research that currently lacks sufficient 
evidence.32
Media reports suggest that trans women in Nepal also 
use hormones bought in private pharmacies.44 45 There is 
poor regulation and monitoring of many drugs dispensed 
through private pharmacies, which make them easily avail-
able without a prescription, but there is a notable lack of 
published research on hormone use.12 Evidence on what 
type of hormones they take, how these are consumed 
(oral or injection), who prescribes them and what are 
the side effects experienced by transgender individuals 
from these hormones are still not known. The IBBS 
survey of Nepal16 reported that about a quarter (24%; 33 
of 139 participants) of transgender individual were using 
hormones, mostly as their own choice or suggested by 
peers. The self-administration of hormones may result in 
a considerable health risk to this subgroup in the popu-
lation. Although the transgender population constitutes 
a small proportion of the total population, it is impera-
tive to understand their healthcare needs and their risk-
taking behaviours to achieve universal health coverage 
as envisioned in the Sustainable Development Goals. 
Against this backdrop, this study explored (1) hormone 
use among trans women, (2) types of hormones used and 
how they are consumed, and (3) side effects experienced 
after hormone use. Findings from this study may help to 
develop health promotion strategies that could improve 
their access to healthcare and enhance their experiences 
of using health services.
MetHODS AnD MAterIAlS
Data collection
In September 2016 to March 2017, we carried out a qual-
itative study comprising eight focus group discussions 
(FGDs) with self-identified trans women aged 18 years 
and older. Participants did not have to be on hormones at 
the time of the study. To capture diverse views, the FGDs 
were carried out in four of the seven different provinces 
(table 1). The research team selected these provinces 
purposively to represent the different geographical areas 
(eg, hill, terai, urban, rural) of the country. The closest to 
a national record is data published in 2019 by Poudel and 
colleagues,46 who estimated 18 704 to 24 216 transgender 
individuals for 2016, without specifying the proportion 
of trans women or men. The number of participants in 
the FGDs ranged from seven to nine persons. Addition-
ally, participants who did not want to share their views 
in a group setting were offered an in-depth interview, 
resulting in three in-depth interviews. We also organised 
six key informant interviews (KIIs) with relevant stake-
holders, including representatives working in non-gov-
ernmental organisations (NGOs) supporting the SGM 
population in Nepal, a district health officer, an HIV 
programme coordinator and two KIIs were with trans 
people.
We invited potential research participants using a 
convenience sampling strategy in close collaboration with 
an NGO called Blue Diamond Society (BDS), which is 
working for the SGM population in Nepal. BDS invited 
participants for the FGDs through its network of regional 
coordinators. The coordinators and local outreach 
workers invited local trans women through word of 
mouth. Due to the stigma attached to being transgender, 
other more public ways of inviting participants were 
deemed to be inappropriate. All FGDs and interviews 
were conducted in Nepali by PRR and SRN who are native 
Nepali speakers and experienced qualitative researchers 
on sensitive health issues. Interviews took place in a loca-
tion agreed with the participants, usually NGO offices. 
With the prior permission from the participants, the FGDs 
and interviews were audio recorded. The researchers 
made short field notes of non-verbal behaviour during 
the qualitative data collection. Most of our FGDs lasted 
between 1 and 2 hours, whereas interviews took between 
45 min and 1 hour.
FGD and interview facilitation tools
Based on the literature, the research team, in collabora-
tion with key stakeholders, drafted a discussion guide47 
to facilitate FGDs48 and interviews.49 The FGD guide 
included knowledge of hormones, first experience with 
hormone, administration of hormones, source of injec-
tion paraphernalia and who injects, experience of side 
effects and its management (copy available from first 
author on request). Prior to the discussion, demographic 
characteristics such as age, education, ethnicity, employ-
ment and duration of hormone use were collected from 
each FGD participant. The questions included in the 
guide were pretested in a similar FGD50 with trans women 
in Kathmandu. This pilot resulted in minor changes to 
the final discussion guides, but as these were not very 
different from the pilot, its findings were included in our 
analysis. The FGD guide was used in all FGDs as a starting 
point and the interview guide was adjusted for each KII 
depending on their background. Thus, the KII guideline 
included questions around hormone use, the uptake of 
healthcare services, specific programme targeting these 
population and programmatic recommendations.
by copyright.
 o
n
 O
ctober 28, 2019 at Bournem
outh Uni Consortia. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030464 on 22 October 2019. Downloaded from 
4 Regmi PR, et al. BMJ Open 2019;9:e030464. doi:10.1136/bmjopen-2019-030464
Open access 
Table 2 Characteristics of focus group discussion 
participants
Sociodemographic 
characteristics (n=62) N (%)
Age (mean±SD) 23.06±3.9 years
Ethnicity*
  Brahmin/Chhetri 26 (41.9)
  Newar 8 (12.9)
  Janajati (including Tharu/
Chanduari)
25 (40.3)
  Dalit 3 (4.8)
Education
  Up to primary (up to 5th grade) 9 (14.5)
  Up to school level (6th to SLC) 34 (54.8)
  Higher (above SLC) 19 (30.6)
Occupation
  Bar dancer 12 (19.4)
  Waiter 14 (22.6)
  Business 4 (6.5)
  NGO/development worker 4 (6.5)
  Sex worker 3 (4.8)
  Modelling/fashion 1 (1.6)
  Unemployed 24 (38.7)
Currently living with
  Friends 24 (38.7)
  Family 24 (38.7)
  Alone 14 (22.6)
Time at current address
  <6 months 15 (24.2)
  >6 months 47 (75.8)
Duration of hormone use
  <6 months 9 (14.5)
  1–3 years 25 (40.3)
  >3 years 18 (29.0)
  Previously used but now 
stopped using
10 (16.1)
*Ethnicity recoded in line with Census of Nepal.
NGO, non-governmental organisation; SLC, School Leaving 
Certificate.
Data organisation and analysis
We transcribed51 the original recordings before trans-
lation into English by a Nepali social scientist, who was 
trained for this study. PRR and SRN (both native Nepali 
speakers) independently reviewed the transcribing and 
translating. Transcripts were crossed checked with orig-
inal recordings. Any disagreements were discussed in 
detail between PRR and SRN for appropriate translation. 
Each transcript had a cover note describing the interviews, 
settings, how the discussion had been any, any differences 
from other interviews, particular incidents, environments 
and a reflection on the issues identified in the session. 
The data were then organised through NVivo V.11.52 As 
part of the thematic analysis, PRR read and coded all 
transcripts and ERvT and SRN did the same for half of 
the transcripts each and acted as second independent 
coders. A thematic approach was followed for data anal-
ysis.53 In the spirit of qualitative research, any differences 
between the first and the second coder were discussed in 
the team until consensus was reached. Relevant quotes 
are presented to illustrate the key themes.54 We followed 
Consolidated criteria for Reporting Qualitative research 
(COREQ) checklist to report FGD and interview data.55
ethical consideration
Our study was conducted in compliance with human 
rights and ethical standards required from studies on 
sensitive issues.56 Written informed consent was obtained 
privately from all research participants prior to the FGDs 
and interviews. Through an information sheet in Nepali, 
participants were provided with enough information 
about the study purpose and procedure, voluntary partic-
ipation, confidentiality, risk and benefits to the partic-
ipants, complaint procedure and so on. Participants’ 
travel costs were reimbursed, but no financial incentives 
were provided.
Patient public involvement
Patient public involvement is a relatively new concept in 
Nepal. However, we involved lay experts (=trans women) 
and relevant key stakeholders from the conceptualisation 
of this study. Our data collection tools and information 
sheet were piloted through an FGD with seven partici-
pants to ensure that they are inclusive and comprehen-
sive. We will also engage them in disseminating results of 
this study, particularly their contribution while developing 
research factsheets in plain language and communicating 
them to transgender individuals will be very valuable.
reSultS
Characteristics of participants
Most FGD participants were young (mean age 23.06±3.9 
years) and the majority (55%) completed grade 6 to high 
school level. About one-third had completed secondary 
education, in Nepal this is called School Leaving Certifi-
cate (equivalent of high school in the USA or secondary 
school in the UK). In terms of ethnicity, Brahmin/Chhetri 
and Janajati groups represented 82% of our FGD sample, 
and Dalits represented 5%. This suggests an under-rep-
resentation of participants from Dalit communities in 
our study compared with the total population in the 
latest census.57 About 39% (n=24) lived with friends; 42% 
(n=26) worked in restaurants/bars and 40% (n=25) had 
been using hormones for 1 to 3 years (table 2). Although 
sex and sexuality are considered as taboo subjects and not 
discussed openly in most Nepali families, our participants 
were actively engaged during the research. More people 
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were invited than attended on the day, but none withdrew 
during the FGDs or interviews.
We identified five partly overlapping themes: (1) 
reasons and motivations for hormone use; (2) accessi-
bility and use of hormones; (3) side effects; (4) partic-
ipants’ health-seeking behaviours overlapping and (5) 
discontinuation of hormone use. Each theme is discussed 
below and is supported and illustrated by relevant quotes.
reasons and motivations for hormone use
The overarching reason for using hormones was to affirm 
to a more feminine gender. Many wanted to look female. 
In the following quote, ‘Diane’ refers to contraceptive 
birth control pills to make one’s skin and hair less greasy:
…I heard about it [=hormone] from my friends. 
First, I searched on YouTube about how a person 
whose appearance is like a boy can become a girl …. 
There are both good and bad effects. But since we 
live only once we all want to be beautiful and fairer, 
isn’t it? And then I started using ‘Diane’. That is from 
Thailand. (FGD1, Kathmandu)
Almost all our FGD participants stated that ‘friends’ 
are the main sources of information about hormones, as 
the quote above already suggested. Some participants, 
particularly from Kathmandu, had acquired information 
about hormones through the internet, mainly YouTube. 
A few participants also mentioned organisations working 
for transgender populations (without naming them 
explicitly) as a source of information on hormones.
Non-prescribed hormone use appears to be common 
and most participants started using hormones after 
encouragement from their friends:
We do [=use hormones] on the basis of friends… 
Friends said that breasts will increase if we use this. 
(In-depth interview 3, Kathmandu)
The key motive for hormone use was to get a feminine 
look. Most participants believed that hormones help 
them change their physical appearance. Some started 
using hormones only after they saw positive changes to 
their friends, as exemplified by this quote:
First of all, I saw my friends using it [=hormone]. 
After seeing good effects on them, I also wanted to 
use it … I am still using it. I used ‘Diane’. (FGD3, 
Kathmandu)
Friends did not have to be close by, or even in Nepal, 
some referred to friends abroad:
I have many friends in India. They are used to taking 
hormone. After using hormone, this [=pointing to 
her breast] increased. Then I also started having the 
desire to use hormone. Then my friend said, “I know 
about this [=hormone], you can get it here.” Then 
that friend took me and I bought it. (In-depth inter-
view 2, Kathmandu)
Access to hormone, types, intake and doses
Hormones were commonly taken as injections or orally. 
Some participants named several brands/trade names 
of hormone (pills and injectable); however, most were 
unware of the types of hormones they were taking. One 
participant stated:
…I do not know the name of hormone. My friends 
bring them [=hormones] for me. I do not normally 
look at the name. (In-depth interview 1, Kathmandu)
When asked about the places to buy/access these 
hormones, it was found that local pharmacies were the 
popular choice for most. Accessing hormones from 
NGOs was also reported but participants did not want to 
share about NGOs in detail. Some even travelled abroad 
to buy these hormones, with Thailand as the preferred 
destination. One FGD participant said, while speaking 
about visiting pharmacists in Thailand, when we ask for a 
specific hormone by name they simply sell it to us.
There was agreement among participants that hormones 
from abroad are of a better quality than the ones available 
locally. There was a notion among our participants that 
hormones from overseas acted faster; therefore, many got 
friends to buy these when they travelled overseas:
…it [=hormone from Bangkok] makes our body soft, 
veins are not visible, our body feels soft like those of 
girls. The medicine that we get here also works but 
takes longer to work. (FGD5, Kathmandu)
Or
Chest development is faster by the medicine from 
Bangkok than here. (FGD1, Kathmandu).
Hormones from abroad were also considered as 
creating effects that lasted longer:
We keep on bringing from there [=overseas] till we 
become beautiful. [Laughing] We bring hormones 
that will be sufficient for many years at a time. (FGD3, 
Kathmandu)
Our findings suggest that trans women in Nepal 
use hormone in an improper way, including using too 
many hormones at the same time for the sake of instant 
outcomes. They seemed not to follow guidance regarding 
recommended doses, for example, one participant stated:
… women who use hormone for family planning take 
one hormonal tablet in a day while TG [=transgen-
der] uses two in the morning and two in the evening 
which will definitely have an effect. So, you have to 
provide information about this [=hormone]. (FGD8, 
Banke)
Without a proper prescription, self-medication leads to 
‘common sense decisions’ about the timing and dose of 
the hormone:
We used to take two tablets in the morning and two in 
the evening when our chests were not large. But now, 
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since our chest has increased and as we felt that it has 
some disadvantages also then I have started taking 
just one in a day. (FGD6, Kaski)
While stigma and fear of the hormones being discov-
ered in one’s belongings, some did not take hormone 
with them when visiting family (especially in rural areas):
I do not carry hormone with me when I go home… I 
do not take it when I stay at home. I take it again after 
I come here. (FGD7, Sunsari)
Self-reported side effects
Frequently reported side effects of hormones were head-
ache, decreased sexual desire, spots (acne) on cheeks and 
forehead, lost appetite, chest pain, vomiting, weight gain, 
shortness of breath, itchy, dizziness, sleepy, feeling weak, 
feeling angry, hair falling out, gain in thigh and buttock 
muscles. Most argued that these hormones/chemicals 
have no benefits to their health, for example, one FGD 
participant said:
There is definitely no benefit. This is just for beauty. 
(FGD2, Kathmandu)
Some participants argued that hormone use can cause 
a range of serious diseases, such as diabetes, cancers, high 
blood pressure and high cholesterol; therefore, it can 
impact on their mental health well-being.
… we can start thinking that we are victims of depres-
sion. Hormone makes us monotonous, we do not like 
to work, we do not feel sleepy but sometimes we feel 
too sleepy, we feel tired, we like to eat too much, we 
like to sleep all the time, body becomes hot, some-
times we feel too hot and sometimes we feel too cold. 
(FGD6, Kaski)
This was also reflected in a different FGD:
We feel very weak … feels like vomiting, tiredness, 
spots on face and there is risk of diabetes, paraly-
sis, blood cancer and breast cancer in the long run. 
(FGD2, Kathmandu)
utilisation of healthcare services
Utilisation of healthcare services to explore about 
hormones or seek help for side effects of hormone use 
was very poor. Although most visited private pharma-
cies for injecting hormones, discussion around types of 
hormones used, side effects or other health issues was 
very poor. The decision to start using oral pills seems to 
be largely based on encouragements from their peers.
Talking about injectable, we go to medical [=pharma-
cy] and get injected …but we did not take hormone 
[=oral pills] by consulting doctors; we took it by fol-
lowing our friends. (FGD1, Kathmandu)
Almost all participants noted that they feel shy and 
generally hesitate to discuss these matters with doctors 
or nurses. Lack of user-friendly services at the healthcare 
centres was frequently reported as a barrier:
It is very shameful when we have to go for check-up. 
We rather die than going for a check-up. There are 
females [=healthcare care worker] and we have a lot 
of problems. (FGD4, Kathmandu)
… No, I did not go anywhere. If I do check-up and 
if they show serious problem then … I had gone to 
teaching hospital once. I had to open my clothes for 
video x-ray. There were boys also. I felt very shy think-
ing that my breasts will be on display. (Participant, 
FGD3, Kathmandu)
Some stressed that there are no specialist healthcare 
professionals on transgender health in Nepal.
… there are no any specialists here [=in Nepal]. 
When we go to Bangkok a number of times, somehow 
specialists are there. There are shops and we get in-
jectable there and return back. (FGD1, Kathmandu)
However, there were a few participants who had 
consulted a health professional when they had problems:
I explained my problem and she recommended some-
thing. After that nothing happened to me [=i.e. there 
was no reaction to be seen]. Then I asked an older 
friend and started using ‘Sunaulo Gulab’ [=an oral 
contraceptive pill in Nepal] by myself. After that I 
became too weak again and I went to the endocrinol-
ogist of Bir Hospital and did some tests. And then I 
became well. (FGD1, Kathmandu)
Discontinuation of hormone use
Participants have no any fixed plan or schedule to stop 
using hormones. The decision to discontinue hormone 
use is often made abruptly by users. Participants reported 
that having side effects (experienced or perceived) are 
the main reasons for discontinuation of hormones.
Actually, I used to take hormone before as well when 
I used to work in the fancy store. I used to go as a 
boy by wearing a jacket. It [=breast] was not too large. 
It was this much [showing with hand]. I used to feel 
shy though it [=breast] was small, so I used to wear 
big jackets and go for work. Then I came here and 
some said that hormone causes this and some said 
hormone causes that so I stopped using hormone. 
Then breasts also started decreasing as I stopped us-
ing hormone. (FGD7, Sunsari)
Others reacted to the views and experiences of people 
like them:
… I used that [=hormone] for about 2–3 years. Then 
people said that hormone caused sugar [=diabetes], 
thyroid and others. Also, one of my older friends 
who has been using hormone for long suffered from 
diabetes, thyroid problems, so I stopped using that 
[=hormone]. (In-depth Interview 2, Kathmandu)
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Some had to discontinue hormone use temporarily 
when their stocks ran out. This was particularly chal-
lenging to those users who bought hormones overseas. 
Discontinuation during home visit was also reported.
… I had left using hormone in the middle but again 
[=name removed] brought hormone from overseas 
some days ago, so I started using that. That [=hor-
mone] has finished now and there was no one who 
would go Thailand. (FGD4, Kathmandu)
Others mentioned not taking hormones when or they 
are ill:
We leave taking it [=hormone] when we are not well 
and we use it when we are well. (FGD8, Banke)
DISCuSSIOn
This is the first study to explore hormone use in Nepali 
trans women. The study identified five key themes 
around hormone use ranging from reasons and moti-
vations for using, accessibility, side effects and health-
seeking behaviours to stopping to take hormones. 
Overall, the peer network of the trans woman and the 
internet media, particularly YouTube, played a signifi-
cant role in disseminating information about hormones 
to the transgender population, of course, this is not 
necessarily medically correct information on hormones. 
Moreover, users require a good level of health literacy in 
English to comprehend most of the online health infor-
mation. Clark and colleagues found that for trans women 
in the USA, having a greater number of hormone-using 
networks and using the internet to find transgender 
friends affected the likelihood of misusing hormones in 
different ways.58 Social science research has suggested 
that network dynamics can affect the behaviour of trans 
women regarding hormone use.58 59
In Nepal, access to information about hormones and 
their use through healthcare providers is alarmingly poor. 
Trans women’s decision to take hormones is largely influ-
enced by their peers and their self-medication is unsuper-
vised, suggesting they are unaware about the types of the 
hormones they use, their side effects or required doses. 
Indeed, seeking sensitive information on sexuality, repro-
ductive health or hormones from peers is not unique to 
Nepal and other Asian countries.60 61 For example, an 
earlier study in Lao found that as few as one in eight of 
those using hormones sought advice from medical profes-
sionals, instead most often relying on friends for informa-
tion about hormones.61
The most frequently reported generic motives for using 
hormones were looking more feminine (ie, developing 
breasts) and beautiful. Participants generally had a poor 
knowledge of hormones and many reported side effects 
from hormone use affecting their mental well-being. 
Hormones should only be prescribed by an authorised 
medical professional37; however, we found that accessing 
hormones through local pharmacies is common. A 
study in India also reported an unwillingness among 
qualified medical practitioners to prescribe hormone 
therapy forcing transgender individuals to self-administer 
hormones.62 There is evidence that utilisation of health-
care professionals by transgender persons is associated 
with their reduction of risk behaviours.63
We found that some trans women buy hormones 
abroad, primarily from Thailand or India; unfortu-
nately, there are no studies on side effects of hormone 
use in South Asia. The notion that one can buy better 
‘quality hormones’ abroad influenced their decision to 
use these particular ones. There may be risks to using 
non-prescribed hormones such as not recognising side 
effects nor seeking medical help when needed. This 
may result in non-adherence to the recommended treat-
ment regime since obtaining medicines remotely involve 
higher costs, travel and legal issues. The WPATH recom-
mends that hormone therapy should only be initiated 
once a psychosocial assessment has been completed and 
informed consent reviewing the risks and benefits of 
starting therapy has been obtained and transgender-spe-
cific guidelines are available for healthcare providers.36
Transgender individuals have many health priorities on 
top of sexual and reproductive health and HIV preven-
tion.6 64 They may face mental health issues due to the 
side effect of hormone use as well as social discrimina-
tion. Transgender individuals feel there is discrimination 
against them in government health centres and a lack 
of user-friendly or transgender specialist services. All 
these factors drive them to seek services from the private 
health sector or overseas which many in Nepal can ill 
afford. This calls for capacity building (eg, specialised 
training, quality services) of all health workers and partic-
ularly health professionals working for the transgender/
SGM population. Capacity building activities should also 
include non-clinical staff such as receptionists or those 
serving at ticket counters as they are the front-line contact 
staff. These activities may help to ensure non-discrimina-
tory behaviours when providing services to transgender 
or other sexual minority populations.12
Globally, individuals who identify as transgender are 
considered as a ‘key population’ for the HIV response 
due to their high-risk sexual behaviours.6 15 17 Programmes 
in Nepal are also HIV and sexual transmitted infec-
tion (STI) centric and ignore the area of hormone use 
in the transgender population. We suggest that Nepali 
trans women’s low knowledge around proper dosing 
of hormones and intermittent access to self-prescribed 
hormone is problematic. If interventions provide training 
to existing staff on hormones and its safe use, these staff 
can easily cascade proper information on hormones to 
their peers just like they are currently doing for HIV and 
STI prevention, treatment and care. For example, there 
are out-reach workers, community mobilisers and peer 
educators who provide HIV and STI-related services to 
the transgender population. We propose that these health 
workers are also trained in providing hormone coun-
selling to this population. In Canada, for example, the 
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Trans Health Connection project initiated in 2011 offers 
in-depth training to primary care providers on different 
issues such as social and medical transition; administra-
tion of hormones and preventative care and supporting 
mental health and well-being through counselling or 
group work.30 In Nepal, the existing strategic behavioural 
and communication materials, providing information on 
HIV/STI targeting transgender individuals, could serve 
as a platform for providing information on hormones.
Strengths and limitations
Despite Nepal being a conservative country where sex 
and sexuality are not openly discussed, most participants 
actively engaged during the FGDs and interviews. Conse-
quently, our data are rich and include diverse views of our 
participants. Offering in-depth interviews to those partic-
ipants who were not willing to participate in the FGD also 
made our data inclusive. As we invited the participants 
through a local NGO that works for transgender commu-
nity, we acknowledge that our participants may be more 
exposed to health and social issues than the rest of trans-
gender individuals. We might have also excluded trans-
gender people who did not want to expose their status 
to this organisation’s network. Although we conducted 
our FGDs in different geographical locations, we may 
have missed the views of trans women elsewhere in Nepal 
who have different sociocultural or behavioural charac-
teristics than our participants, but we managed to cover 
all major ethnic groups. Although we invited participants 
regardless of their previous exposure to hormones, all 
had used or were using some types of hormones. Finally, 
all researchers were male in this study, which may have 
influenced the data collection.
COnCluSIOn
Hormone therapy is used by some Nepali trans women to 
medically affirm their gender identity through feminisa-
tion of their appearance. Peer networks and the internet 
are key sources for learning about hormones and for 
disseminating information to this transgender popula-
tion. Very few in our sample sought doctors’ advice and 
prescription when accessing hormone therapy as also 
reported by the 2018 IBBS survey of Nepal.16 Our find-
ings suggest that hormones are more likely to be bought 
from either local private pharmacies or abroad through 
friends; this kind of self-medication of hormones in trans 
women bring with it a range of risks to the physical and 
mental health of transgender individuals. Existing inter-
ventions targeting transgender individuals in Nepal may 
act as a platform when providing information, educa-
tion and communication around hormone therapy. The 
latter needs to be embedded into existing services to 
support trans people and offer them informed choice in 
gender-affirming care. More research is needed into the 
nature of self-medication through hormones and their 
health and side effects; these studies need a longitudinal 
element and include the measurement of QoL.
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